Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this study is to learn how long-term use of estrogen affects blood vessels in healthy adults.
Participants will:
Researchers will compare blood vessel function of those who take estrogen to those who do not.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Continuous estrogen/progestin | Females who have had continuous estrogen/progestin treatment for a minimum of 1 year. |
| |
| No Estrogen/progestin | Females who have not had continuous estrogen treatment for a minimum of 5 years. |
| |
| Continuous progestin | Females who have had continuous progestin treatment for a minimum of 1 year. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nω-nitro-L-arginine methyl ester (L-NAME) | Drug | L-NAME will be infused locally through microdialysis catheters. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in blood vessel dilation | Cutaneous vascular conductance in response to acetylcholine, L-NAME, and sodium nitroprusside infusions will be calculated as percentage of cardiovascular conductance. | 2 hours |
| Change in Perfused Vessel Density | Total vessel density (TVD) will be calculated using the DeBacker Score manual analysis on all images that have a minimum microcirculation image quality score (MIQS) of 10. Perfused vessel density (PVD) will be calculated by multiplying total vessel density (TVD) x proportion of perfused vessels (PPV%). | 0.5 hours |
Not provided
Not provided
Inclusion Criteria:
Estrogen/Progestin Group
Exclusion Criteria:
Medications that could alter cardiovascular control
Rash, skin disease, or pigmentation disorders on both forearms
Anemia
Kidney Disease
Known skin allergies
Smoking or tobacco use within last 6 months
Coronary Artery Disease
-1 cardiovascular risk factor Hypertension Diabetes Hypercholesterolemia Hyperlipidemia
Bleeding disorders
Use of anti-coagulants
Allergies to study drugs
Use of topical/non-topical steroids in last 6 months
Internal mouth sores
Forearms covered with tattoos
Pregnancy
Not provided
Not provided
Community sample
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Froedtert Hospital | Wauwatosa | Wisconsin | 53226 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D019331 | NG-Nitroarginine Methyl Ester |
| D000109 | Acetylcholine |
| D009599 | Nitroprusside |
| ID | Term |
|---|---|
| D001120 | Arginine |
| D024361 | Amino Acids, Basic |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided
Not provided
Not provided
Not provided
whole blood
| Acetylcholine | Drug | ACh will be infused locally through microdialysis catheters. |
|
| Sodium Nitroprusside | Drug | SNP will be infused locally through microdialysis catheters. |
|
| D000599 |
| Amino Acids, Diamino |
| D001679 | Biogenic Amines |
| D000588 | Amines |
| D009930 | Organic Chemicals |
| D005292 | Ferricyanides |
| D003486 | Cyanides |
| D000838 | Anions |
| D007477 | Ions |
| D004573 | Electrolytes |
| D007287 | Inorganic Chemicals |
| D005290 | Ferric Compounds |
| D058085 | Iron Compounds |
| D006856 | Hydrogen Cyanide |
| D017672 | Nitrogen Compounds |